The ROE as of September 2024 (TTM) for Enliven Therapeutics, Inc. (ELVN) is -29.31%

According to Enliven Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -29.31%. This represents a change of 297.30% compared to the average of -7.38% of the last 4 quarters.

Enliven Therapeutics, Inc. (ELVN) Historical ROE (quarterly & annually)

How has ELVN ROE performed in the past?

The mean historical ROE of Enliven Therapeutics, Inc. over the last ten years is 37.43%. The current -29.31% ROE has changed -178.30% with respect to the historical average. Over the past ten years (40 quarters), ELVN's ROE was at its highest in in the December 2022 quarter at 35.71%. The ROE was at its lowest in in the December 2019 quarter at -25.07%.

Enliven Therapeutics, Inc. (ELVN) ROE by Quarter and Year

Discovering the peaks and valleys of Enliven Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Enliven Therapeutics, Inc. (ELVN) Average ROE

How has ELVN ROE performed in the past?

The current ROE of Enliven Therapeutics, Inc. (ELVN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Enliven Therapeutics, Inc. (ELVN) ROE vs. Peers

How is ELVN’s ROE compared to its peers?

Enliven Therapeutics, Inc.’s ROE is greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Immuneering Corporation (-66.03%), greater than Aerovate Therapeutics, Inc. (-83.65%), greater than MoonLake Immunotherapeutics (-11.05%), greater than Structure Therapeutics Inc. (-20.15%), greater than Compass Therapeutics, Inc. (-28.67%), greater than Replimune Group, Inc. (-52.15%), greater than Nuvectis Pharma, Inc. (-152.26%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Kronos Bio, Inc. (-68.82%), greater than Gossamer Bio, Inc. (-117.33%), greater than Eliem Therapeutics, Inc. (-47.03%), less than Inhibrx, Inc. (1.62%), greater than Merrimack Pharmaceuticals, Inc. (-35.28%), greater than Celcuity Inc. (-60.83%),

Build a custom stock screener for Enliven Therapeutics, Inc. (ELVN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enliven Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Enliven Therapeutics, Inc. (ELVN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Enliven Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.